Send Email

Working Hours

Mon-Fri 08:00AM - 06:00PM

Need Any Help?


Product Detail

  • Sotorasib
  • Sotorasib
  • Sotorasib
  • Sotorasib


  • CAS No.2296729-00-3:
  • MF:C30H30F2N6O3:
  • MW:560.6:
  • Reference standard: In-House:
  • Documentation:TP:
  • Inquiry

Product Description

Sotolacib, an acrylamide-derived KRAS inhibitor, was developed by Amgen and is currently in clinical trials for the treatment of solid tumors with KRAS G12C mutations. This mutation accounts for more than 50% of all KRAS mutations. It is the first experimental KRAS inhibitor. The drug currently in development [MRTX849] has the same target.

Hits: 【Print】